AQC
0.015
200%
BMO
0.001
-50%
YRL
0.18
102.2%
BOT
0.155
-50%
PFE
0.023
91.7%
IPB
0.005
-44.4%
FAL
0.375
87.5%
CDE
0.023
-39.5%
LKO
1.38
84%
BMG
0.007
-36.4%
ICR
0.014
75%
LIC
4.57
-35.1%
ATH
0.015
66.7%
AKN
0.004
-33.3%
QXR
0.005
66.7%
ECT
0.002
-33.3%
RMI
0.02
66.7%
PNT
0.01
-33.3%
WR1
0.23
58.6%
LOC
0.13
-25.7%
NGY
0.031
55%
BLZ
0.003
-25%
ALR
0.003
50%
GTR
0.003
-25%
AUK
0.003
50%
UNT
0.006
-25%
JAY
0.003
50%
URF
0.32
-22.9%
KCC
0.06
50%
W2V
0.007
-22.2%
SFM
0.21
50%
CPO
0.011
-21.4%
DY6
0.3
46.3%
SKM
0.19
-20.8%
IBX
0.016
45.5%
OLY
0.12
-20%
PGY
0.013
44.4%
ORD
0.32
-20%
RDG
0.01
42.9%
HMX
0.029
-19.4%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Nyrada Inc. (ASX:NYR): Developing NYR-BI03

Nyrada Inc. (ASX:NYR) has made progress on developing NYR-BI03, a first in class neuroprotection treatment for both traumatic brain injury (TBI) and stroke.

– Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.

– Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03.

– Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024

ASX announcement: https://announcements.asx.com.au/asxpdf/20240806/pdf/066by3mf9gs2jy.pdf

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved